Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
23.29
+0.45 (1.97%)
Nov 5, 2024, 4:00 PM EST - Market closed
Viridian Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Cash & Equivalents | 107.67 | 102.83 | 155.58 | 42.3 | 45.9 | 24.85 | Upgrade
|
Short-Term Investments | 463.7 | 374.54 | 268.97 | 154.67 | 81.74 | 2 | Upgrade
|
Cash & Short-Term Investments | 571.37 | 477.37 | 424.55 | 196.97 | 127.64 | 26.85 | Upgrade
|
Cash Growth | 70.92% | 12.44% | 115.55% | 54.31% | 375.47% | -57.03% | Upgrade
|
Receivables | - | 0.1 | 0.1 | 0.45 | - | 0.3 | Upgrade
|
Prepaid Expenses | 10.3 | 9.01 | 6.52 | 2.65 | 1.97 | 2.59 | Upgrade
|
Other Current Assets | - | - | - | 0.1 | - | - | Upgrade
|
Total Current Assets | 581.66 | 486.48 | 431.17 | 200.16 | 129.61 | 29.74 | Upgrade
|
Property, Plant & Equipment | 3.34 | 3.34 | 2.94 | 2.06 | 0.79 | 0.52 | Upgrade
|
Other Long-Term Assets | 0.66 | 0.6 | 0.98 | 1.49 | 0.86 | - | Upgrade
|
Total Assets | 585.66 | 490.42 | 435.09 | 203.71 | 131.26 | 30.26 | Upgrade
|
Accounts Payable | 3.14 | 2.24 | 14.23 | 2.33 | 0.67 | 1.1 | Upgrade
|
Accrued Expenses | 29.76 | 23.17 | 18.11 | 10.4 | 9.06 | 3.43 | Upgrade
|
Current Portion of Long-Term Debt | 2.96 | - | - | - | - | 3.98 | Upgrade
|
Current Portion of Leases | 0.51 | 0.84 | 0.61 | 0.52 | 0.46 | - | Upgrade
|
Current Unearned Revenue | 0.29 | 0.29 | 0.29 | 0.29 | 0.3 | - | Upgrade
|
Other Current Liabilities | 0.1 | 0.1 | 0.1 | 0.1 | 0.19 | 1.68 | Upgrade
|
Total Current Liabilities | 36.76 | 26.64 | 33.35 | 13.64 | 10.67 | 10.18 | Upgrade
|
Long-Term Debt | 17.49 | 20.21 | 4.65 | - | - | 4.33 | Upgrade
|
Long-Term Leases | 1.65 | 0.99 | - | - | - | - | Upgrade
|
Long-Term Unearned Revenue | 0.43 | 0.57 | 0.86 | 1.15 | - | - | Upgrade
|
Other Long-Term Liabilities | 0 | - | 1.17 | 1.21 | 0.54 | - | Upgrade
|
Total Liabilities | 56.33 | 48.4 | 40.03 | 15.99 | 11.22 | 14.51 | Upgrade
|
Common Stock | 0.64 | 0.54 | 0.41 | 0.24 | 0.04 | 0.02 | Upgrade
|
Additional Paid-In Capital | 1,169 | 960.54 | 741.07 | 412.1 | 218.09 | 183.9 | Upgrade
|
Retained Earnings | -839.44 | -725.91 | -488.17 | -358.3 | -278.89 | -168.17 | Upgrade
|
Comprehensive Income & Other | -0.54 | 0.34 | -0.39 | -0.16 | -0.01 | - | Upgrade
|
Total Common Equity | 329.63 | 235.51 | 252.92 | 53.88 | -60.76 | 15.75 | Upgrade
|
Shareholders' Equity | 529.34 | 442.02 | 395.06 | 187.72 | 120.04 | 15.75 | Upgrade
|
Total Liabilities & Equity | 585.66 | 490.42 | 435.09 | 203.71 | 131.26 | 30.26 | Upgrade
|
Total Debt | 22.61 | 22.04 | 5.26 | 0.52 | 0.46 | 8.3 | Upgrade
|
Net Cash (Debt) | 548.76 | 455.33 | 419.29 | 196.45 | 127.18 | 18.54 | Upgrade
|
Net Cash Growth | 67.63% | 8.60% | 113.44% | 54.46% | 585.96% | -64.47% | Upgrade
|
Net Cash Per Share | 10.05 | 10.17 | 13.07 | 16.48 | 35.76 | 8.88 | Upgrade
|
Filing Date Shares Outstanding | 63.89 | 62.77 | 42.9 | 25.91 | 7.23 | 3.54 | Upgrade
|
Total Common Shares Outstanding | 63.88 | 53.99 | 41.31 | 23.92 | 4.23 | 2.32 | Upgrade
|
Working Capital | 544.9 | 459.84 | 397.82 | 186.53 | 118.94 | 19.56 | Upgrade
|
Book Value Per Share | 5.16 | 4.36 | 6.12 | 2.25 | -14.36 | 6.78 | Upgrade
|
Tangible Book Value | 329.63 | 235.51 | 252.92 | 53.88 | -60.76 | 15.75 | Upgrade
|
Tangible Book Value Per Share | 5.16 | 4.36 | 6.12 | 2.25 | -14.36 | 6.78 | Upgrade
|
Machinery | - | 2.05 | 2.22 | 1.4 | 3.01 | 3.13 | Upgrade
|
Leasehold Improvements | - | 0.67 | 1.11 | 0.75 | 0.74 | 0.74 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.